Lu et al. suggested that anti-VEGFR-2-AF is a prospective therapeutic Ab for prostate cancer treatment that inhibits angiogenesis, through vascular endothelial cells, and tumorigenesis at the same time by VEGFR-2-expressing tumor cells [118]. This evidence concerns the gene KDR and prostate carcinoma.